Published in Blood on May 15, 1998
Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance. Am J Hum Genet (1999) 1.74
Fas gene mutation in the progression of adult T cell leukemia. J Exp Med (1999) 1.07
Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma. Am J Pathol (1999) 0.98
Loss of the nf1 tumor suppressor gene decreases fas antigen expression in myeloid cells. Am J Pathol (2004) 0.92
A portrait of the Bcl-2 protein family: life, death, and the whole picture. J Clin Immunol (1999) 0.90
Low frequency of FAS mutations in Reed-Sternberg cells of Hodgkin's lymphoma. Am J Pathol (2003) 0.82
Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. Sci Transl Med (2017) 0.78
FAS system deregulation in T-cell lymphoblastic lymphoma. Cell Death Dis (2014) 0.78
Analysis of single nucleotide polymorphisms in the FAS and CTLA-4 genes of peripheral T-cell lymphomas. J Hematop (2008) 0.76
Clinical and oncological significance of aberrant Fas (APO-1/CD95) isoform expression in adult T-cell leukemia. Indian J Clin Biochem (2000) 0.75
Gene defects in the soma: some get it and some don't! J Clin Invest (2010) 0.75
Regulation of cell death in cancer-possible implications for immunotherapy. Front Oncol (2013) 0.75
Two CD95 (APO-1/Fas) signaling pathways. EMBO J (1998) 10.42
Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) Nature (1995) 8.23
Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science (1989) 7.76
Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature (1995) 4.95
Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science (1995) 4.80
New insights to the MLL recombinome of acute leukemias. Leukemia (2009) 4.07
Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia (1995) 4.04
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet (1998) 3.91
Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med (2000) 3.77
Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest (1993) 3.13
Characterization of a human preadipocyte cell strain with high capacity for adipose differentiation. Int J Obes Relat Metab Disord (2001) 2.94
Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia (2009) 2.78
TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11). Oncogene (1991) 2.71
Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med (1996) 2.65
The MLL recombinome of acute leukemias in 2013. Leukemia (2013) 2.55
Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood (1999) 2.48
Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol (1993) 2.45
Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction. Lancet (1991) 2.33
Cellular stress response and apoptosis in cancer therapy. Blood (2001) 2.32
Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res (1997) 2.32
Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia (2009) 2.30
Site-specific deletions involving the tal-1 and sil genes are restricted to cells of the T cell receptor alpha/beta lineage: T cell receptor delta gene deletion mechanism affects multiple genes. J Exp Med (1993) 2.23
Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. Leukemia (2000) 2.21
Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood (1994) 2.11
Phlebitis rate and time kinetics of short peripheral intravenous catheters. Infection (2004) 2.06
[Bilateral salivary gland swelling with pitfalls]. Med Klin (Munich) (1994) 2.03
mAb33 from transduction laboratories specifically binds human CD95-L. Cell Death Differ (2000) 1.97
Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group. Leukemia (1996) 1.96
Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene (2001) 1.94
Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood (2000) 1.93
Regulation of apoptosis in the immune system. Curr Opin Immunol (1994) 1.89
The human formin-binding protein 17 (FBP17) interacts with sorting nexin, SNX2, and is an MLL-fusion partner in acute myelogeneous leukemia. Proc Natl Acad Sci U S A (2001) 1.82
TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur J Immunol (1998) 1.81
Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia (2007) 1.79
The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res (1997) 1.76
Prethymic phenotype and genotype of pre-T (CD7+/ER-)-cell leukemia and its clinical significance within adult acute lymphoblastic leukemia. Blood (1989) 1.74
Diabetic retinopathy in pediatric patients with type-1 diabetes: effect of diabetes duration, prepubertal and pubertal onset of diabetes, and metabolic control. J Pediatr (1998) 1.72
Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group. J Clin Oncol (1995) 1.72
Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am (2000) 1.69
CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J Neurosci (1999) 1.66
High-level secretion of tumor necrosis factor-alpha contributes to hematopoietic failure in hairy cell leukemia. Blood (1989) 1.64
Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia (2003) 1.64
A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer (1995) 1.59
The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia (2010) 1.56
Activation of apoptosis pathways in peripheral blood lymphocytes by in vivo chemotherapy. Blood (2001) 1.51
The MLL recombinome of acute leukemias. Leukemia (2006) 1.51
High expression of APO-1 (CD95) on T lymphocytes from human immunodeficiency virus-1-infected children. Blood (1994) 1.50
MycN sensitizes neuroblastoma cells for drug-induced apoptosis. Oncogene (1999) 1.46
Activation of the CD95 (APO-1/Fas) system in T cells from human immunodeficiency virus type-1-infected children. Blood (1996) 1.46
Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Münster Group. Leukemia (1998) 1.44
New insights into the biology of Philadelphia-chromosome-positive acute lymphoblastic leukaemia using a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques at the single cell level. Br J Haematol (1997) 1.43
Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J Biol Chem (1998) 1.41
Transcript synthesis and surface expression of the interleukin-2 receptor (alpha-, beta-, and gamma-chain) by normal and malignant myeloid cells. Blood (1996) 1.40
[Indicators for quality evaluation of inpatient patient care in an ENT clinic]. HNO (1998) 1.40
Resting energy expenditure, weight loss, and altered body composition in HIV infection. Nutrition (1996) 1.38
Involvement of CD95/Apo1/Fas in cell death after myocardial ischemia. Circulation (2000) 1.36
Resistance of cultured peripheral T cells towards activation-induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death-inducing signaling complex. Eur J Immunol (1997) 1.33
Evidence for genetic regulation of susceptibility to toxoplasmic encephalitis in AIDS patients. J Infect Dis (1996) 1.32
Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene (2001) 1.32
Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95. Klin Padiatr (2005) 1.32
Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression. Cancer Res (2000) 1.31
Cytotoxic drugs and the CD95 pathway. Leukemia (1999) 1.30
Betulinic acid: a new cytotoxic agent against malignant brain-tumor cells. Int J Cancer (1999) 1.28
A powerful DNA extraction method and PCR for detection of microsporidia in clinical stool specimens. Clin Diagn Lab Immunol (1999) 1.26
Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood (1996) 1.26
Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement. Leukemia (2007) 1.25
Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood (1998) 1.25
Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases. Proc Natl Acad Sci U S A (1999) 1.25
Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int J Cancer (1998) 1.24
Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia (2009) 1.24
Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia (2000) 1.23
Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. EMBO J (1997) 1.23
[Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83)]. Klin Padiatr (1987) 1.23
Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia (2004) 1.21
Detection of microsporidia (Enterocytozoon bieneusi) in intestinal biopsy specimens from human immunodeficiency virus-infected patients by PCR. J Clin Microbiol (1995) 1.21
Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood (1993) 1.20
Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells. Leukemia (1997) 1.19
Cytoreduction and prognosis in childhood acute lymphoblastic leukemia. J Clin Oncol (1996) 1.18
c-Jun-dependent CD95-L expression is a rate-limiting step in the induction of apoptosis by alkylating agents. Mol Cell Biol (2000) 1.18
Molecular analysis of the CALM/AF10 fusion: identical rearrangements in acute myeloid leukemia, acute lymphoblastic leukemia and malignant lymphoma patients. Leukemia (2000) 1.18
Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia (2012) 1.16